## Sub

## WE CLAIM:

- 1. An isolated or recombinant immunogenic polypeptide which comprises, mimics or cross-reacts with a B-cell or T-cell epitope of a *Lawsonia spp.* OmpH polypeptide.
- 2. The isolated or recombinant immunogenic polypeptide of claim 1 capable of eliciting the production of antibodies against *Lawsonia spp.* when administered to an avian or porcine animal.
- 3. The isolated or recombinant immunogenic polypeptide of claim 1 capable of conferring a protective immune response against *Lawsonia spp*. when administered to an avian or porcine animal.
- 4. The isolated or recombinant immunogenic polypeptide of claim 2 wherein the Lawsonia spp. is L. intracellularis.
- 5. The isolated or recombinant immunogenic polypeptide of claim 3 wherein the Lawsonia spp. is L. intracellularis. 7
- 6. An isolated or recombinant immunogenic polypeptide selected from the following:
  - (i) a peptide, oligopeptide or polypeptide which comprises an amino acid sequence which has at least about 70% sequence identity overall to the amino acid sequence set forth in SEQ ID NO: 1;
  - (ii) a homologue, analogue or derivative of (i) which mimics a B-cell or T-cell epitope of a *Lawsonia spp*. OmpH polypeptide.
- 7. The isolated or recombinant immunogenic polypeptide of claim 6 capable of eliciting the production of antibodies against *Lawsonia spp.* in a porcine or avian animal.
- 8. The isolated or recombinant immunogenic polypeptide of claim 7 capable of conferring a protective immune response against *Lawsonia spp*. in a porcine or avian animal.

- 64 -

9. The isolated or recombinant immunogenic polypeptide of claim 8, capable of inducing humoral immunity against *Lawsonia spp*. in a porcine or avian animal.

Juh A4

- 10. The isolated or recombinant immunogenic polypeptide of claim 9, capable of inducing humoral immunity against Lawsonia spp. in a porcine animal.
- 11. The isolated or recombinant immunogenic polypeptide of claim 8 wherein the Lawsonia spp. is L. intracellularis.
- 12. The isolated or recombinant immunogenic polypeptide of claim 10 wherein the Lawsonia spp. is L. intracellularis.
- 13. The isolated or recombinant immunogenic polypeptide of claim 6 that comprises the amino acid sequence set forth in SEQ ID NO: 1 or the amino acid sequence encoded by the OmpH-encoding nucleotide sequence of pALK13 (ATCC 207196) and is capable of eliciting the production of antibodies against *Lawsonia intracellularis* when administered to an avian or porcine animal.
- 14. The isolated or recombinant immunogenic polypeptide of claim 13 that consists essentially of the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence encoded by the OmpH-encoding nucleotide sequence of pALK13 (ATCC 207196).
- 15. The isolated or recombinant immunogenic polypeptide of claim 13 or 14 capable of inducing a protective immune response against *Lawsonia intracellularis* in a porcine or avian animal.
- 16. The isolated or recombinant immunogenic polypeptide of claim 15 capable of inducing a protective immune response against *Lawsonia intracellularis* in a porcine animal.



17. A vaccine composition for the prophylaxis or treatment of infection of an animal by *Lawsonia spp.*, said vaccine composition comprising an immunogenic component

which comprises an isolated or recombinant polypeptide having at least about 70% sequence identity overall to the amino acid sequence set forth in SEQ ID NO: 1 or an immunogenic homologue, analogue or derivative thereof which is immunologically cross-reactive with *Lawsonia intracellularis*; and one or more carriers, diluents or adjuvants suitable for veterinary or pharmaceutical use.

- 18. The vaccine composition according to claim 17 wherein the *Lawsonia spp.* is *L. intracellularis*.
- 19. The vaccine composition according to claim 18 wherein the immunogenic component comprises an isolated or recombinant polypeptide that comprises the amino acid sequence set forth in SEQ ID NO: 1 or the amino acid sequence encoded by the OmpH-encoding nucleotide sequence of pALK13 (ATCC 207196)...
- 20. The vaccine composition of claim 19, wherein the immunogenic component consists essentially of the amino acid sequence of SEQ ID NO: 1.
- 21. A combination vaccine composition for the prophylaxis or treatment of infection of an animal by *Lawsonia spp.*, said vaccine composition comprising:
  - (i) a first immunogenic component which comprises an isolated or recombinant polypeptide having at least about 70% sequence identity overall to the amino acid sequence set forth in SEQ/ID NO: 1 or an immunogenic homologue, analogue or derivative thereof which is immunologically cross-reactive with Lawsonia intracellularis;
  - (ii) a second immunogenic component comprising an antigenic *L. intracellularis* peptide, polypeptide or protein; and
  - (iii) one or more carriers diluents or adjuvants suitable for veterinary or pharmaceutical use.
- 22. A vaccine vector that comprises, in an expressible form, an isolated nucleic acid molecule having a nucleotide sequence that encodes an isolated or recombinant immunogenic polypeptide which comprises the amino acid sequence set forth in SEQ

ID NO: 1, such that said immunogenic polypeptide is expressible at a level sufficient to confer immunity against *Lawsonia spp.*, when administered to a porcine or avian animal.

- 23. The vaccine vector of claim 22 wherein the immunogenic polypeptide is expressed using the steps of:
  - (i) placing an isolated nucleic acid molecule which comprises the nucleotide sequence set forth in SEQ ID NO: 2 or degenerate variant, a homologue, analogue or derivative thereof which has at least about 70% sequence identity thereto, in operable connection with a promoter sequence;
  - (ii) introducing the isolated nucleic acid molecule and promoter sequence of step
  - (a) into the vaccine vector; and
  - (iii) incubating, growing, or propagating the vaccine vector for a time and under conditions sufficient for expression of the immunogenic polypeptide encoded by said nucleic acid molecule to occur.
- 24. The vaccine vector of claim 23 wherein the Lawsonia spp. is L. intracellularis.
- 25. A polyclonal or monoclonal antibody molecule that is capable of binding specifically to a OmpH polypeptide or a derivative of a OmpH polypeptide that is derived from *Lawsonia spp.* and has at least about 70% sequence identity overall to the amino acid sequence set forth in SEQ ID NO: 1.
- 26. The antibody molecule of claim 25 wherein the OmpH polypeptide or derivative thereof comprises the amino acid sequence set forth in SEQ ID NO: 1.
- 27. A method of diagnosing infection of a porcine or avian animal by *Lawsonia* intracellularis or a microorganism that is immunologically cross-reactive thereto, said method comprising the steps of contacting a biological sample derived from said animal with the antibody molecule of claim 25 for a time and under conditions sufficient for an antigen:antibody complex to form, and then detecting said complex formation.

- 28. The method of claim 27 wherein the biological sample comprises whole serum, lymph nodes, ileum, caecum, small intestine, large intestine, faeces or a rectal swab derived from a porcine animal.
- 29. A method of identifying whether or not a porcine or avian animal has suffered from a past infection, or is currently infected, with *Lawsonia intracellularis* or a microorganism that is immunologically cross-reactive thereto, said method comprising contacting blood or serum derived from said animal with the immunogenic polypeptide of claim 1 for a time and under conditions sufficient for an antigen:antibody complex to form and then detecting said complex formation.
- 30. An isolated nucleic acid molecule which comprises a sequence of nucleotides which encodes, or is complementary to a nucleic acid molecule that encodes, a peptide, oligopeptide or polypeptide selected from the group consisting of:
  - (i) a peptide, oligopeptide or polypeptide which comprises an amino acid sequence which has at least about 70% sequence identity overall to the amino acid sequence set forth in SEQ ID NO: 1; and
  - (iii) a homologue, analogue or derivative of (i) which mimics a B-cell or T-cell epitope of Lawsonia spp.
- 31. The isolated nucleic acid molecule of claim 30, wherein the peptide, oligopeptide or polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or the amino acid sequence encoded by the OmpH-encoding nucleotide sequence of pALK13 (ATCC 207196) or a B-cell epitope or T-cell epitope thereof.
- 32. The isolated nucleic acid molecule of claim 31 comprising the nucleotide sequence set forth in SEQ ID NO: 2 or a complementary nucleotide sequence thereto, or a degenerate variant thereof.
- 33. The isolated nucleic acid molecule of claim 32 consisting essentially of the nucleotide sequence of SEQ ID NO: 2 or a degenerate variant thereof.

- 34. A method of detecting *Lawsonia intracellularis* or related microorganism in a biological sample derived from a porcine or avian animal subject, said method comprising the steps of hybridising one or more probes or primers derived from the nucleotide sequence set forth in SEQ ID NO: 2 or a complementary nucleotide sequence thereto to said sample and then detecting said hybridisation using a detection means.
- 35. The method of claim 34 wherein the biological sample comprises whole serum, lymph nodes, ileum, caecum, small intestine, large intestine, faeces or a rectal swab derived from a porcine animal.
- 36. The method of claim 34 wherein the detection means comprises any nucleic acid based hybridisation or amplification reaction.
- 37. A probe or primer having at least about 15 contiguous nucleotides in length derived from SEQ ID NO: 2 or a complementary nucleotide sequence thereto.
- 38. A plasmid designated pALK13 (ATCC Accession No. 207196).
- 39. The combination vaccine according to claim 21 wherein the second immunogenic component comprises an antigenic *L. intracellularis* peptide, polypeptide or protein selected from the group consisting of SodC, FlgE, hemolysin and autolysin.